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years. If 25 latanoprost patients were treated instead 
with travoprost, one new VFD would be avoided over 
5 years. CONCLUSION: According to our model, the
better control of both mean IOP and IOP variance by
travoprost should better preserve patient vision. Prospec-
tive data collection should be performed to conﬁrm our
ﬁndings.
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OBJECTIVE: To estimate the medical outcome of 
glaucoma/ocular hypertension (OH) treatment in France
according to usual practice. METHODS: Ophthalmolo-
gists selected at random had to include 4 consecutive
patients older than 18 seen in consultation during a week,
2 with glaucoma and 2 with OH. Socio-demographics,
general and eye comorbidities, glaucoma risk factors,
visual acuity (VA), papilla, and visual ﬁelds were col-
lected. A visual ﬁeld defect (VFD) was deﬁned as a dete-
rioration of papilla exam and visual ﬁeld since diagnosis.
A treatment switch was deﬁned as adding a new drug 
or changing any of the current treatments. Time to failure
of a treatment regimen, broken out by the number of
treatment switches, was compared using the likelihood
ratio applied to survival curves. RESULTS: One hundred
and twenty seven of the 337 patients included by the 84
ophthalmologists had their full treatment documented
from diagnosis. Twelve patients developed a new VFD
after diagnosis (average follow-up: 2.5 years). No statis-
tically signiﬁcant difference on the known confounding
factors of VFD was found between patients with and
without VFD. Patients with VFD had a lower VA (-1.23;
P < 0.08). At 3 years, 2.7% of the patients with no treat-
ment switch had a VFD, compared to 22.6% with one
treatment switch and 46.3% with >2 treatment switches.
The difference between the three groups was statistically
signiﬁcant (P < 0.01). CONCLUSION: Patients with
fewer treatment switches have less VFD. Under isotropic
hypotheses, effective treatment strategies should be used
ﬁrst line in order to avoid visual ﬁeld defect and there-
fore protect long-term patient vision.
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Skin diseases have a strong impact on physical and mental
well-being of the patient. These diseases can appear at any
age and, generally speaking, they have a greater reper-
cussions on the quality of life of women. Dermatological
conditions often alter the patient’s own body image,
which can cause psychological problems such as depres-
sion, anxiety and even suicide. OBJECTIVE: To evaluate
the depressive symptomatology (DS) of patients with 
psoriasis. The CES-D (Center for Epidemiologic Studies—
Depression scale), a short self-report scale composed of
20 items, is a questionnaire designed to measure DS in
the general population. The CES-D is widely used in epi-
demiological surveys on large populations. METHOD:
One thousand ﬁve hundred CES-D questionnaires were
sent via a psoriasis patients support group: the APLCP.
The questionnaires once completed were sent back trough
a prepaid envelope. RESULTS: Six hundred thirty-seven
questionnaires were returned: response rate: 42.5%. The
sex ratio Men/Women was 46/54. Mean age: 48.9 years.
Mean age of diagnosis: 25.7 years. The average to the
total score was 20.9 (sd:12.5). The preliminary results
showed DS in 48% of patients with psoriasis (versus 19%
in the general population). There is DS in 47.1% of men
and 49.0% of women. Two groups were identiﬁed: 
ﬂare-up of psoriasis (46.7%), psoriasis not in ﬂare-up
(51.8%)—no answers (1.5%). Current episode of 
psoriasis are linked with higher frequency of DS (54.3%
versus 42.4%). Psoriasis had a greater impact on patients
with episode: CES-D score: 22.8 (sd:12.74) than patients
without present episode CES-D score : 19.22 (s.d :11.96).
This difference was signiﬁcant (p < 0.0003). CONCLU-
SION: Psoriasis patients have an increased risk of DS
compared to the general population (48% versus 19%).
A recent episode of psoriasis results in a more important
frequency of DS in patients (54.3% versus 42.4%).
Appropriate disease management and any treatment that
could reduce ﬂare-up frequency would improve patients’
quality of life and help them face their psoriasis.
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OBJECTIVES: To evaluate the consequences of local
anti-glaucoma drug side effects on the vision-related
quality of life of French patients. METHODS: A mail
survey was sent to 20,000 homes belonging to the Sofres
panel (representative of the French population according
to the quota method) asking whether one member of 
the family was treated with one of the available topical
anti-glaucoma drugs. A computer-assisted telephone
interviewing system was used to conﬁrm self-reported
glaucoma treatment, to describe the disease and its treat-
